Profile of activity of a new anti-inflammatory agent, ST 679 (MED 15).
ST 679 dose-dependently inhibited carrageenan-, concanavalin A-, and nystatin-induced oedema. Studies in rats with adjuvant arthritis showed that a long dosing regimen inhibited primary and secondary lesions. ST 679 was significantly active in reducing the severity of the already established disease and, when given in a short course at the time of adjuvant injection, permanently prevented the development of secondary lesions. Experimental allergic encephalomyelitis in guinea-pigs was not affected by ST 679.
Arrigoni-Martelli
E
E
Research and Development, Sigma Tau S.p.A., Pomezia, Rome, Italy.
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D001169:Arthritis, Experimental / Q000188:drug therapy; D002351:Carrageenan; D003208:Concanavalin A; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy; D005260:Female; D005998:Glycine / Q000031:analogs & derivatives* / Q000494:pharmacology; D007249:Inflammation / Q000188:drug therapy*; D009761:Nystatin; D011758:Pyrroles / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains
D000894:Anti-Inflammatory Agents, Non-Steroidal; D011758:Pyrroles; C065762:ST 679; D003208:Concanavalin A; D009761:Nystatin; D002351:Carrageenan; D005998:Glycine